Catalyst Pharmaceuticals, Inc. (CPRX) Report Analysis
Corporate Events
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell Small Cap Comp Value Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell Small Cap Comp Value Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 2500 Value Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 2500 Value Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 3000E Value Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 3000E Value Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 2000 Value Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 2000 Value Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell Microcap Value Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell Microcap Value Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 3000 Value Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 3000 Value Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 2000 Value-Defensive Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) dropped from Russell 2000 Value-Defensive Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 3000 Growth Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 3000 Growth Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 2000 Growth Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 2000 Growth Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell Small Cap Comp Growth Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell Small Cap Comp Growth Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 3000E Growth Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 3000E Growth Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 2000 Growth-Defensive Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 2000 Growth-Defensive Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell Microcap Growth Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell Microcap Growth Index
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 2500 Growth Index
2022-06-24 00:00:00
Catalyst Pharmaceuticals, Inc.(NasdaqCM:CPRX) added to Russell 2500 Growth Index
Catalyst Pharmaceuticals, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 04:00 PM
2022-05-17 12:03:00
Catalyst Pharmaceuticals, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 04:00 PM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Patrick J. McEnany, Co-Founder, Chairman, President & CEO.
Catalyst Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 11:00 AM
2022-05-17 12:03:00
Catalyst Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 11:00 AM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Patrick J. McEnany, Co-Founder, Chairman, President & CEO.
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022
2022-05-10 20:11:00
Catalyst Pharmaceuticals, Inc. continued to forecast full year 2022 total revenues to be in the range of between $195 million and $205 million, representing a 38% - 45% increase in total revenues as compared to 2021.
Tranche Update on Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX)'s Equity Buyback Plan announced on March 22, 2021.
2022-05-10 16:08:00
From January 1, 2022 to March 31, 2022, the company has repurchased 400,000 shares, representing 0.39% for $2.55 million. With this, the company has completed the repurchase of 2,608,292 shares, representing 2.52% for $14.64 million under the buyback announced on March 22, 2021.
Catalyst Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 11, 2022
2022-04-25 12:03:00
Catalyst Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 11, 2022
Catalyst Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022
2022-04-25 12:03:00
Catalyst Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 10, 2022
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022
2022-02-28 18:21:00
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022
2022-02-14 21:00:00
Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for Full Year 2022
2022-02-07 13:03:00
Catalyst Pharmaceuticals, Inc. provided revenue guidance for full year 2022. The Company forecasts 2022 full year total revenues to be in the range of between $195 million and $205 million, representing a 38%-45% increase in total revenues as compared to 2021.
Catalyst Pharmaceuticals Reports the FDA Marketing Approval Previously Granted for Ruzurgi® Is No Longer Valid
2022-02-03 13:03:00
Catalyst Pharmaceuticals Inc. reported that the District Court which heard Catalyst's Lawsuit against the FDA has entered summary judgment in favor of Catalyst. The District Court's order implements the prior decision of the U.S. Court of Appeals for the 11th Circuit, which ruled that the United States Food and Drug Administration's approval of Ruzurgi® for the treatment of pediatric patients with Lambert-Eaton myasthenic syndrome violated Catalyst's exclusivity for FIRDAPSE® Tablets 10 mg under the Orphan Drug Act. As a result of the District Court's order, the FDA marketing approval previously granted for Ruzurgi® is no longer valid.
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of A Phase 3 Study for Firdapse® (Amifampridine) in Japan
2021-12-06 12:00:00
Catalyst Pharmaceuticals, Inc. announced that its collaboration partner DyDo Pharma has initiated a Phase 3 registration study in Japan to evaluate the efficacy and safety of Catalyst's FIRDAPSE® (amifampridine) 10 mg tablets for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS"). Catalyst entered into a sub-license agreement with DyDo to develop and commercialize FIRDAPSE in Japan in June 2021. Under the terms of the agreement, Catalyst will provide clinical and commercial supply to DyDo and technical support to obtain regulatory approval for the product from the Japanese regulatory authorities. DyDo is responsible for the development and commercialization of the product in Japan pending regulatory approval, and Catalyst will be entitled to development and sales milestones and revenue for clinical and commercial supply of the product.
Catalyst Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021
2021-11-22 15:06:00
Catalyst Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.
Catalyst Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM
2021-11-16 06:30:00
Catalyst Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM.
Tranche Update on Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX)'s Equity Buyback Plan announced on March 22, 2021.
2021-11-09 16:08:00
From July 1, 2021 to September 30, 2021, the company has repurchased 949,746 shares, representing 0.92% for $5.05 million. With this, the company has completed the repurchase of 1,749,746 shares, representing 1.69% for $9.02 million under the buyback announced on March 22, 2021.
Catalyst Pharmaceuticals, Inc. - Shareholder/Analyst Call
2021-10-26 20:46:00
AGM
Catalyst Pharmaceuticals, Inc., Annual General Meeting, Dec 03, 2021
2021-10-26 20:46:00
Catalyst Pharmaceuticals, Inc., Annual General Meeting, Dec 03, 2021, at 09:00 US Eastern Standard Time. Agenda: To elect seven directors to serve a term of one year or until their successors are duly elected and qualified, or until their earlier death, resignation, or removal; to approve an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by 5 million shares; to approve, on an advisory basis, the 2020 compensation of our named executive officers as set forth herein; to ratify Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; and to transact such other business as may properly come before the meeting.
Catalyst Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 10, 2021
2021-10-25 12:03:00
Catalyst Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 10, 2021
Catalyst Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 09, 2021
2021-10-25 12:03:00
Catalyst Pharmaceuticals, Inc. announced that they will report Q3, 2021 results After-Market on Nov 09, 2021
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021
2021-10-25 10:00:00
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.
Catalyst Pharmaceuticals, Inc. Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS
2021-09-30 16:08:00
Catalyst Pharmaceuticals, Inc. reported that it has received a positive decision from the 11thCircuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administration’s (FDA) approval of another amifampridine product, Ruzurgi®, for pediatric patients with Lambert-Eaton myasthenic syndrome (LEMS) despite existing Orphan Drug exclusivity for Catalyst’s Firdapse® (amifampridine) Tablets 10 mg. With this ruling, the 11thCircuit Court panel has reversed the District Court’s decision and remanded the matter to the District Court with instructions to enter summary judgment for Catalyst. The Court's decision adopted Catalyst’s core argument that the FDA’s approval of Ruzurgi® violated Catalyst's rights to Orphan Drug Exclusivity. Catalyst Pathways®, as Catalyst’s patient services program, is only open for adults LEMS patients to enroll, but its staff is available to answer questions from the parents of pediatric LEMS patients and the physicians treating them on available access for pediatric LEMS patients to obtain Firdapse®. These include: Catalyst’s Expanded Access Program which can provide investigational product to pediatric LEMS patients. Catalyst will provide support if a prescriber wishes to file an investigator initiated Investigational New Drug Application (IND) with the FDA, including Catalyst providing investigational product once the physician’s IND is active. In addition, Catalyst will approach FDA to discuss expanding the Firdapse® approval to include pediatric LEMS, though any effort to do so will take time and is not guaranteed.
Catalyst Pharmaceuticals, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 09:05 AM
2021-09-17 19:04:00
Catalyst Pharmaceuticals, Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-21-2021 09:05 AM.
Catalyst Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM
2021-09-11 06:47:00
Catalyst Pharmaceuticals, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.
Catalyst Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 01:20 PM
2021-09-10 19:03:00
Catalyst Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 01:20 PM. Venue: New York, United States.
Catalyst Pharmaceuticals, Inc. Appoints Mary Coleman as Vice President, Head of Investor Relations
2021-08-16 20:13:00
Catalyst Pharmaceuticals, Inc. announced that Mary Coleman has been appointed to the newly created position of Vice President, Head of Investor Relations. This position will report to the Chief Executive Officer of Catalyst. Ms. Coleman joins Catalyst with more than 20 years of investor relations and corporate communications experience in the biotechnology and specialty pharmaceutical industry.
Tranche Update on Catalyst Pharmaceuticals, Inc. (NasdaqCM:CPRX)'s Equity Buyback Plan announced on March 22, 2021.
2021-08-09 16:35:00
From April 1, 2021 to June 30, 2021, the company has repurchased 732,951 shares, representing 0.71% for $3.67 million. With this, the company has completed the repurchase of 800,000 shares, representing 0.77% for $3.96 million under the buyback announced on March 22, 2021.
Catalyst Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 10, 2021
2021-07-26 12:03:00
Catalyst Pharmaceuticals, Inc., Q2 2021 Earnings Call, Aug 10, 2021
Catalyst Pharmaceuticals, Inc. to Report Q2, 2021 Results on Aug 09, 2021
2021-07-26 12:03:00
Catalyst Pharmaceuticals, Inc. announced that they will report Q2, 2021 results After-Market on Aug 09, 2021
Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021
2021-07-21 14:31:00
Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.
Catalyst Pharmaceuticals, Inc. Appoints Dr. Preethi Sundaram as Chief Product Development Officer
2021-07-06 12:03:00
Catalyst Pharmaceuticals, Inc. announced the appointment of Dr. Preethi Sundaram, Ph.D. as Chief Product Development Officer. This position will report to the Chief Executive Officer. Dr. Sundaram has more than 20 years' experience leading, managing, and mentoring teams delivering lifesaving medicines to patients. Since 2005, Dr. Sundaram was employed in various positions at Sanofi, S.A. spanning R&D and Medical Affairs, including as Global Clinical Research Director, International Development, Global Project Head, Multiple Therapeutic Area Programs, and more recently as Global Head Medical Operations, General Medicines Business Unit. Prior to joining Sanofi, Dr. Sundaram held leadership positions at Abbott Labs and Covance.
Catalyst Pharmaceuticals Announces the Appointment of Molly Harper to its Board of Directors
2021-06-29 12:03:00
Catalyst Pharmaceuticals, Inc. announced the appointment of Molly Harper to the Company’s Board of Directors. Since May 2020, Ms. Harper has served as Executive Vice President of Operations for Relmada Therapeutics, Inc.
Fundamental Summary
Catalyst Pharmaceuticals released impressive Q1 results on 2022-05-10. Their growth, value, and income factors indicate a well-executed and balanced strategy, which is generating exciting growth. We expect that this positive performance will continue in the coming months, and anticipate that Catalyst Pharmaceuticals will maintain good momentum even in a challenging environment. We gave Catalyst Pharmaceuticals a 84 rating and a BUY recommendation.
Catalyst Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 43.09 million compared to USD 30.21 million a year ago. Net income was USD 13.24 million compared to USD 7.66 million a year ago. Basic earnings per share from continuing operations was USD 0.13 compared to USD 0.07 a year ago. Diluted earnings per share from continuing operations was USD 0.12 compared to USD 0.07 a year ago.
Business Description
Catalyst Pharmaceuticals, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals in May 2015. Catalyst Pharmaceuticals was founded in 2002 and is based in Coral Gables, Florida.
Sector Overview
Catalyst Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Catalyst Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 22.6 | 7.7% | 58 | |
| Net Cashflow | 51.0 | 23.9% | 77 | |
| Capital Expenditure | -0.1 | 89.2% | 98 | |
| Asset Turnover | 0.7 | 5.7% | 87 | |
| Free Cashflow | 0.6 | 9.7% | 81 |
* All values are TTM
The below chart reflects Catalyst Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Catalyst Pharmaceuticals's peer average final assessment score stands on 67.0, Catalyst Pharmaceuticals's score is 84.
- CPRX
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Catalyst Pharmaceuticals's stock is now priced above its 5-day and 200-day, but below its 50-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a positive setup in the near and long-term. In particular, many institutional investors keep close watch of the 200-day moving average. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Catalyst Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators don't clearly signal directional momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 62.
5D MA
6.78
50D MA
7.16
200D MA
6.85
MACD
-0.11
RSI
10.48
STOCH
74.71
Balance Sheet Analysis
Overall, Catalyst Pharmaceuticals's critical balance sheet metrics appear to signal strong support and a high likelihood of positive growth going forward. Catalyst Pharmaceuticals publishes solid book value factor metrics in this report. Price to book ratio (P/B) now sits at 3.1 and represents a -7.9% change from the previous report. These book value factor numbers show that management has been prudent in focusing on efficient growth. We believe the stock price has room to grow to reflect its intrinsic value accurately. Consequently, their book value factors movement received a grade of 86. Also, Catalyst Pharmaceuticals's management was effective in improving its cash and cash equivalents metrics, which now sit at 178.4. This represents 4.0% change from the last reporting period. Its impressive cash and cash equivalents metrics should support upward pressure on its's stock price. Therefore, its cash and cash equivalents movement earned a score of 77. At the same time, one critical balance sheet metric, Liabilities, was notably weak. At filing, Catalyst Pharmaceuticals's liabilities were 26.8, representing a -13.6% change from the previous period. Catalyst Pharmaceuticals's liabilities changes appear mediocre compared to their peers. Contextually, they convey that management finds balancing asset growth, resource allocation, and liabilities challenging. Discouraging results like these statistically lead to negative movement in stock prices, so we rated their liabilities movement component 52. Their balance sheet, therefore, earned a score of 75.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 247.0 | 3.9% | 69 |
| Liabilities | 26.8 | -13.6% | 52 |
| Price to Book | 3.1 | -7.9% | 86 |
| Cash & Equivalents | 178.4 | 4.0% | 77 |
| Equity | 220.2 | 6.5% | 70 |
The below chart describes Catalyst Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Catalyst Pharmaceuticals received a balance sheet score of 75, the average of its peers stands on 68.0.
- CPRX
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 2 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 5 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 7 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 8 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 16 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 20 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 21 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 22 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 24 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 33 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 35 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 37 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 41 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 43 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 45 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 51 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 59 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 63 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 65 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 74 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 87 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Overall, Catalyst Pharmaceuticals's critical income statement metrics appear to strongly support positive growth going forward. Catalyst Pharmaceuticals's management was effective in improving its EBIDTA, which now sits at 60.5 and represents a 14.3% change from the last reporting period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. The company is headed in the right direction regarding EBITDA, exhibiting efficient capital controls and strong overall financial performance. Therefore, its EBITDA component earned a score of 88. Also, Catalyst Pharmaceuticals's reported return on equity (ROE) ratio was 22.6, representing a change of 7.7%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 58. That said, one metric, Revenue Efficiency, stood out as particularly concerning. Catalyst Pharmaceuticals management did an underwhelming job managing revenue efficiency this past period. Catalyst Pharmaceuticals's revenue efficiency is 153.7 according to the metrics in the current filing, which represents a 9.1% change from the previous report. This metric might have a 13.1 percent impact on companies in the same industry and with the same market capitalization. Their revenue efficiency does not make a compelling case for upward pressure on the company's stock price. Consequently, their revenue efficiency received a grade of 48. Therefore, their income statement earned a grade of 77.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | 60.5 | 14.3% | 88 |
| Total Revenues | 153.7 | 9.1% | 48 |
| Return on Equity | 22.6 | 7.7% | 58 |
The below chart describes Catalyst Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Catalyst Pharmaceuticals received a income statement score of 77 , the average of its peers stands on 67.0.
- CPRX
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 2 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 5 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 7 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 8 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 15 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 16 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 20 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 21 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 22 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 24 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 33 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 35 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 41 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 43 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 45 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 51 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 63 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 65 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 74 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 87 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 88 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Overall, Catalyst Pharmaceuticals's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. Catalyst Pharmaceuticals's management did a great job this period managing its capital expenditure (CapEx). In terms of the raw numbers, CapEx was reported as -0.1, which represents a 89.2% change from the last period. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. The company's CapEx movement, therefore, received a grade of 98. Also, Catalyst Pharmaceuticals is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.7, representing a 5.7% change from the previous period. Companies in the same sector and market capitalization will usually be affected by up to 4.1 percent by this parameter. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. The company's asset turnover movement, therefore, received a grade of 87. On the other hand, Net Cash Flow, jumped out as looking problematic. Catalyst Pharmaceuticals's net cash flow metrics were 51.0 according to their current filing, which represents a 23.9% change from the previous report. As demonstrated by these concerning net cash flow metrics, their priorities seem to be headed in the wrong direction. Its net cash flow, therefore, received a grade of 77. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 87.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 51.0 | 23.9% | 77 |
| Capital Expenditure | -0.1 | 89.2% | 98 |
| Asset Turnover | 0.7 | 5.7% | 87 |
| Free Cashflow | 0.6 | 9.7% | 81 |
The below chart describes Catalyst Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Catalyst Pharmaceuticals received a cash flow score of 87, the average of its peers stands on 69.0.
- CPRX
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 2 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 5 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 6 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 7 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 8 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 9 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 10 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 16 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 20 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 21 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 22 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 24 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 33 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 35 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 41 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 43 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 45 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 51 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 63 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 65 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 74 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 87 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.